Analyst Coverage

The following organisations provide research coverage on Pharmaxis: 

 msta hm

MST Access Services Pty Limited
Analyst: Chris Kallos
Senior Life Science Analyst

MST Access initiated coverage on 1 November 2021
Read MST Access reports below:

12 November 2021 New indication for PXS-5505
1 November 2021 Initiation of Coverage

 Taylor Collison

Taylor Collison Ltd

Analyst: Dennis Hulme

Taylor Collison initiated coverage on 30 November 2021
For copies of current reports contact Taylor Collison.

Initiation Report: Pharmaxis - Exploring Efficacy in Cancer and Fibrosis 30 November 2021


Blake Industry and Market Analysis Pty Ltd
Editors: David Blake and Mark Pachacz (
Read Bioshares most recent reports:

19 April 2021

Karst Peak Continues Investment in Austalia Biotech

15 February 2021

Pharmaxis Makes First Commercial Bronchitol Shipment to USA

3 November 2020

Bronchitol FDA Approval a Turning Point for Pharmaxis

7 September 2020

Boehringer Ends Development of Pharmaxis Compound

10 August 2020

A Big Six Months Ahead for Pharmaxis

4 May 2020

Pharmaxis - Multiple Assets to Drive Value

24 February 2020

Pharmaxis Remains Confident of Securing LOXL2 Deal

24 December 2019

Top Six Stock Picks – 2020

19 December 2019

Boehringer Ingelheim Discontinues
NASH Program; Continues in Diabetic Retinopathy

28 October 2019

PXS Completes Phase Ia Trial of PXS5505A

24 June 2019

Pharmaxis' Bronchitol Edges Closer to FDA Approval

13 May 2019

Pharmaxis Gains Positive Vote for Bronchitol in USA

29 April 2019

Pharmaxis Update

25 February 2019

Pharmaxis Tackles the Intractable

25 January 2019

Pharmaxis' LOXL2 Program Ready for a Deal

10 December 2018

Pharmaxis Investor Briefing Summary

12 October 2018

More Positive Phase I Data from LOXL2 Program

13 August 2018 Pharmaxis strengthens balance sheet ahead of LOXL2 licensing deal
20 July 2018 Interview with Dr Kathleen Metters
8 May 2018

Pharmaxis – a drug developer with a deal making record

5 February 2018 A busy year for Pharmaxis – multiple trial readouts ahead
8 September 2017

Pharmaxis – Boehringer selects diabetic retinopathy as second indication

4 September 2017

Pharmaxis' partner starts phase II NASH trial

24 March 2017

Three share price drivers for Pharmaxis

28 October 2016 Pharmaxis. All attention on NASH for Pharmaxis

Emerald FinancialEmerald Financial
Analyst: Alfred Chan
Read Emerald Financial most recent reports:

18 May 2021 Initial report


Bell Potter logo1Bell Potter Securities Limited
Analyst: Tanushree Jain (

Bell Potter initiated coverage on 8 December 2017.
For copies of current reports contact Bell Potter.

13 February 2021

1H21 – Result Summary

7 January 2021

FDA approval for Bronchitol revamps the business, improves outlook

7 September 2020

BI terminates agreement, discontinues
development of partnered drug

19 August 2020

FDA clears IND for myelofibrosis study

13 August

FY20 Audited Results - No Material Change

5 August 2020

Key catalysts expected in Q4CY20

22 May 2020

COVID-19 impacting timing for key catalysts

13 February 2020

1H20 Audited Results - No Material Change

6 February 2020

Down but not out, with turnaround prospects strong in CY20

25 November 2019

Approaching key inflection points

16 August 2019

FY19 Audited Results - No material change

30 July 2019

Key catalysts coming up in FY20

24 June 2019

FDA Issues CRL on Bronchitol - approval now expected in early 2020

15 May 2019

Bronchitol gets positive recommendation from Adcom by a narrow majority


15 February 2019

Strong cash position and approaching key inflection points

30 April 2018

Interim data from Phase 1 LOXL-2 program strengthen partnering prospects

16 February 2018 1H18 Results - no material change from unaudited results released earlier
1 February 2018

Good clinical and partnering progress on LOXL-2 asset

11 January 2018

BI milestone strengthens balance sheet, LOXL-2 moves into the clinic

8 December 2017

Emerging as a key player in multi-billion dollar NASH market